Research programme: Parkinson's disease therapeutics - NeuroLifeSciences

Drug Profile

Research programme: Parkinson's disease therapeutics - NeuroLifeSciences

Alternative Names: NLS-5/COP2Q; NLS-6/COP5F; NLS-7/COP SF

Latest Information Update: 04 Dec 2015

Price : $50

At a glance

  • Originator NeuroLifeSciences
  • Developer NLS Pharma
  • Class Quinolines; Quinoxalines; Tryptamines
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Parkinson's disease

Most Recent Events

  • 04 Dec 2015 Preclinical trials in Parkinson's disease in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top